Iptacopan Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 200mg
Reference Brands: Fabhalta (USA/EU)
Category:
Immune Disorder
Iptacopan is an oral complement factor B inhibitor developed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder in which red blood cells are destroyed by the immune system. By inhibiting factor B, Iptacopan prevents the activation of the alternative complement pathway, reducing hemolysis and improving hemoglobin levels. It is taken orally and offers a convenient alternative to intravenous complement inhibitors like eculizumab or ravulizumab.
Iptacopan is available in Capsules
and strengths such as 200mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Iptacopan is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Iptacopan can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing